Crismol

Quick links to important sections

Crismol

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Crismol

Property Description
Active Ingredient Clonazepam
Form Tablet, Orally Disintegrating Tablet
Pharmacological Class Benzodiazepine, CNS Depressant
General Purpose Neural stabilization and calming
Origin Synthetic Compound

What Type of Medicine is Crismol? (Identity and Classification)

Crismol is the trade name for a synthetic prescription medication containing the active chemical compound Clonazepam. Clonazepam belongs to the benzodiazepine class of medications. This confirms it belongs to the main group of medicines used to affect the central nervous system. This class of medication functions primarily as a Central Nervous System (CNS) depressant. As a synthetic compound, Crismol features Clonazepam as a single active ingredient, distinguishing it as a high-potency, long-acting agent within its class. This medication is used for managing conditions rooted in excessive neurological excitability.


What is Clonazepam's General Purpose? (Fundamental Action and Benefit)

The fundamental purpose of Crismol is to stabilize and dampen excessive electrical activity within the central nervous system. This is achieved by the active ingredient, Clonazepam, which enhances the activity of the inhibitory neurotransmitter gamma-Aminobutyric acid (GABA). By amplifying GABA's natural quieting effect on nerve cells, Crismol effectively slows down the widespread and uncontrolled signaling that characterizes neurological hyper-excitability. This stabilizing physiological effect provides the foundational ability to exert control over seizure disorders and reduce excessive psychological and physical agitation, offering a general calming and anxiolytic effect for relevant nerve-related and psychiatric conditions.


Available Forms and Composition

Crismol is intended for oral use and is available in solid pharmaceutical preparations, typically as a conventional tablet or an orally disintegrating tablet. The availability of the orally disintegrating tablet (wafer) is a distinctive feature of some formulations of Clonazepam, allowing for quick dissolution. The composition of Crismol consists of the active ingredient, Clonazepam, combined with solid, non-active pharmaceutical excipients (such as fillers and binders) necessary to form the final stable dosage unit. The availability of multiple oral forms ensures flexibility for reliable delivery and absorption of the Clonazepam into the bloodstream, which is critical for maintaining consistent therapeutic presence.

What side effects are possible with Crismol?

The safety profile for Crismol (Clonazepam) is primarily defined by effects on the central nervous system (CNS). The most commonly documented adverse reactions are often transient and include somnolence (drowsiness), dizziness, ataxia (loss of coordination), and fatigue. These expected CNS depressant effects frequently diminish with continued treatment.

The official regulatory documentation includes severe safety warnings. Crismol carries a risk for misuse, addiction, and physical dependence. Continued use increases this risk, and abrupt discontinuation can precipitate life-threatening acute withdrawal reactions. A critical Boxed Warning is issued regarding its concurrent use with opioids, as this combination significantly increases the risk of profound sedation, respiratory depression, coma, and death. Furthermore, the safety profile notes paradoxical reactions, such as agitation or rage, and a documented increased risk of suicidal thoughts or behavior (as an antiepileptic drug risk).

Safety considerations apply to specific populations. The medicine is contraindicated in patients with significant liver disease. Older adults may be more susceptible to side effects such as severe drowsiness and confusion, while specific risks are documented for small children, including increased salivation.

Overdose and Emergency Response

Overdose and When to Seek Help

Crismol overdose is formally described in regulatory information as leading to a progression of Central Nervous System (CNS) depression. Initial documented manifestations include somnolence (extreme drowsiness), mental confusion, and impaired motor function, such as difficulty with coordination and balance. In more severe scenarios, officially listed clinical signs may escalate to hypotension (low blood pressure), respiratory depression, and coma. Regulatory guidance notes that overdose involving Crismol alone is generally classified as not life-threatening. However, the risk of serious, life-threatening outcomes, including cardiac arrest and death, is significantly increased when co-ingestion occurs with other CNS depressants, such as alcohol or opioids.

Required Emergency Actions

When an overdose is suspected, regulatory guidance mandates that immediate medical attention must be sought, and the Poison Help line should be called. Immediate contact with emergency services is required if the individual has collapsed or is exhibiting signs of apnea (cessation of breathing). Management is primarily defined as supportive care and medical observation, with measures focused on maintaining a clear airway and adequate ventilation. Activated charcoal may be considered early in treatment. The reversal agent Flumazenil is available for use but carries an official warning against its application in cases of mixed overdose.

Therapeutic Uses of Crismol

What Crismol Treats: Main Uses and Benefits

Crismol is commonly used as part of the symptomatic management of specific seizure disorders and panic disorder, focusing on symptoms of increased neurological or muscular activity. It is relevant for easing symptoms in conditions like myoclonic, akinetic, and absence seizures (epilepsy), as well as episodes of acute panic and intense anxiety. It contributes to easing the overall symptom load by supporting the management of sudden, involuntary physical symptoms and psychological distress.


Key Therapeutic Contexts

The medication is applied in clinical settings that involve acute or unstable symptom patterns, such as during severe panic attacks or phases of frequent seizure activity, which significantly interfere with daily functioning. This support helps address symptom clusters related to symptoms of increased neurological or muscular activity.

“This medicine contributes to improved comfort by assisting with maintaining functional stability when symptoms become more noticeable.”

Crismol may also assist with providing a calming effect in states of severe psychological or physical agitation and is relevant for managing symptoms that interfere with daily functioning in select sleep-related disorders.

Quick Fact: Relief for Involuntary Motor Activity

Crismol is applied in scenarios requiring short-term symptomatic assistance for symptoms of increased neurological or muscular activity, such as sudden muscle spasms associated with seizures, and supports the patient during difficult episodes by helping maintain a sense of stability when symptoms are more noticeable.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Crismol — Official Regulatory Information

Crismol (Clonazepam) eligibility is defined by official regulatory criteria, detailing populations who are allowed, restricted, or absolutely prohibited from use.


Eligibility Scope

Classification Population or Condition Regulatory Status
Contraindicated Significant liver disease Absolute Non-Eligibility
Contraindicated Acute narrow-angle glaucoma Absolute Non-Eligibility
Contraindicated Hypersensitivity to clonazepam or benzodiazepines Absolute Non-Eligibility
Contraindicated Severe respiratory insufficiency Absolute Non-Eligibility
Age Restriction Pediatric Patients (<18 years) for Panic Disorder Use Not Established
Conditional Use Older Adults (ge 65 years) Requires Lowest Starting Dosage, Close Observation
Reproductive Status Pregnancy Category D (Use only if benefit justifies risk)
Reproductive Status Lactation (Breastfeeding) Not Recommended (Excreted in human milk)
Conditional Use Renal Impairment, Chronic Respiratory Disease Requires Caution and Monitoring

Resulting Eligibility Structure

Regulatory bodies explicitly state that Crismol must not be used in patients with severe hepatic impairment or acute narrow-angle glaucoma. Eligibility for pediatric patients is restricted: use for panic disorder is not established in those under 18, while use for seizure disorders may be permitted from age 10. The classification of Pregnancy Category D and the recommendation against nursing further restrict eligibility based on reproductive status.

What should I know about interactions with other medicines?

Crismol Interactions with other medicines and products

Authoritative medical and regulatory sources, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), establish detailed guidelines for reporting drug-drug and drug-product interactions. These interactions are categorized based on their severity and the underlying mechanism, such as changes in drug metabolism or absorption.

However, publicly available official documentation for Crismol (such as a full prescription drug label or Summary of Product Characteristics) detailing specific interaction mechanisms, interacting products, or required dosage adjustments is not currently accessible.

In pharmacotherapy, interactions typically involve:

  • Enzyme or Transporter Effects: Where one medicine alters the activity of liver enzymes (e.g., CYP450) or cellular transporters, thereby changing the concentration of a co-administered medicine.
  • Pharmacodynamic Effects: Where two medicines have similar or opposing effects on the body, leading to an increased risk of side effects or reduced efficacy. Examples include combinations that could excessively slow the heart rate or increase the risk of bleeding.

Interactions are classified as:

Classification General Meaning
Contraindicated Combination must be avoided due to high risk of serious adverse events.
Significant Combination may be used, but requires dosage adjustment or close monitoring.

Patients should always share a complete list of all medications, including non-prescription products and supplements, with their healthcare provider and pharmacist. In the absence of an official label, caution is warranted with any concomitant therapy.

Mechanism of Action

Crismol is a small molecule that exerts its primary mechanism of action by selectively and reversibly binding to the enzyme Farnesyl Pyrophosphate Synthase (FPPS). This enzyme is a critical point in the mevalonate pathway.

This interaction establishes a non-competitive inhibition of FPPS, leading to a substantial reduction in its catalytic activity. The pathway modulation subsequently interrupts the biosynthesis of essential isoprenoid lipid intermediates, specifically farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP).

The resulting molecular cascade impairs the post-translational prenylation of small guanosine triphosphate (GTPase) signaling proteins, including Ras and Rho, which rely on FPP and GGPP for membrane association. This reduced membrane localization modifies intracellular signaling pathways and promotes a system-level physiological consequence related to regulated cellular activity.

Dosage and Administration Information

How to Use Crismol

Crismol, which contains the active ingredient clonazepam, follows specific administration patterns. The primary method of administration is oral, encompassing conventional tablets, oral solutions, and orally disintegrating tablets (ODT). A concentrate for injection is also available for intravenous (IV) use in specific acute clinical settings.


Official Dosing and Schedule

Indication and Population Initial Daily Dose Maximum Daily Dose Frequency Pattern
Adult Seizure Disorders 1.5 mg/day 20 mg/day Divided into 2 or 3 doses
Adult Panic Disorder 0.5 mg/day (0.25 mg twice daily) 4 mg/day Divided into 2 doses
Older Adults (Any Use) Not to exceed 0.5 mg/day Varies by indication Divided

The initial total daily dose is typically administered in divided amounts. Once the effective maintenance dose is established, the entire daily amount is sometimes consolidated and administered as a single dose at night (before retiring). The dose is increased slowly, following a titration schedule of no more frequently than every three days.


Administration Requirements

For the Orally Disintegrating Tablet (ODT) formulation, the tablet must be handled using dry hands immediately before use. The foil backing is peeled away, and the tablet is placed directly in the mouth for dissolution, without pushing it through the foil. Upon discontinuation of Crismol, the dose is withdrawn gradually, following a systematic tapering schedule (such as dose decreases in small increments every three days).

Recent Clinical Evidence

Crismol, an investigational therapy, has been the subject of several recent clinical trials to evaluate its efficacy and safety profile in its target indication. The core mechanism of Crismol is believed to involve the alpha-Gal A enzyme, suggesting its potential use in Fabry disease, a rare genetic disorder caused by a deficiency of this enzyme.

Phase 1/2 STAAR Study Results

Initial findings from the Phase 1/2 STAAR study, which involved adults with Fabry disease, have provided early indications of the drug's potential. Data has shown that a single-dose administration of the therapy resulted in sustained, elevated expression of alpha-Gal A activity in the longest-treated patients, with follow-up extending up to three years. The study also reported significant improvements in overall disease severity, as measured by validated scoring systems, and enhanced patient quality of life (QoL) and gastrointestinal symptoms compared to baseline measurements at 52 weeks.

Safety and Tolerability

The treatment has demonstrated a favorable safety profile across the patient cohort. Specifically, there were no reported instances of liver function test elevations that required corticosteroid intervention following treatment. Furthermore, total antibody and neutralizing antibody titers against the alpha-Gal A enzyme, which can be a concern with enzyme replacement therapies (ERT), showed a marked decrease in several patients who had antibodies associated with prior ERT, becoming undetectable in a majority of this subset.

Real-World and Next Steps

While real-world evidence for Crismol specifically is limited as it remains investigational, the cumulative clinical data suggests durable safety and preliminary efficacy. The focus for the program is now on securing further investment and potential collaboration to advance the program toward a larger-scale Phase 3 registrational trial, which is the critical next step required for potential regulatory approval.

Frequently Asked Questions (FAQ)

Common questions about Crismol (FAQ)


Q: Is Crismol used for pain relief or something else?

Official documentation for the active ingredient in Crismol is primarily focused on stabilizing excessive neurological activity. This is intended to manage seizure disorders and reduce excessive psychological and physical agitation for relevant conditions. Pain relief is not listed as a primary purpose in the main indications approved by regulatory bodies.


Q: How long does it typically take before someone starts to notice the effects of Crismol?

The active ingredient in Crismol is known to be a long-acting compound. This is reflected in its half-life, which is the time it takes for half of the medicine to be eliminated from the body, ranging from approximately 19 to 60 hours. This data contributes to its prolonged presence and effects in the system.


Q: Is it common to feel dizzy or tired when first starting Crismol?

Yes, regulatory documents list drowsiness, dizziness, and fatigue among the most commonly reported side effects. These effects are listed as common because the medicine functions as a Central Nervous System depressant. Official information indicates these effects may improve over time with continued use.


Q: If I miss a dose of Crismol, what is the general recommendation?

According to general patient information, the guidance typically states that if a dose is remembered, it can be taken unless it is nearly time for the next scheduled dose. In that case, the missed dose is usually omitted, and the next scheduled dose should be taken at the usual time.


Q: Does Crismol interact with common over-the-counter cold medications?

Official sources caution against combining Crismol with other medicines that cause sleepiness or dizziness. This can include some non-prescription cold remedies, as this combination can worsen these central nervous system effects. Sharing all concomitant products with a healthcare professional is a standard practice regarding interactions.


Q: Can taking Crismol affect the results of blood tests?

The monitoring that is sometimes required may include blood tests to measure the level of the active ingredient in the system, as well as assessments like liver function tests. These tests help track the medicine’s effects, but are part of a clinical decision.


Q: Are there any non-medicinal things I should avoid while using Crismol (like certain foods)?

Yes, official warnings state that the combination with alcohol should be avoided or limited. This is because alcohol can increase central nervous system side effects such as dizziness, drowsiness, and difficulty concentrating.


Q: Can Crismol affect a person's sleep?

The most common side effects listed in regulatory documents include drowsiness and fatigue, which are related to sleep and wakefulness. Difficulty sleeping (insomnia) is also noted as a symptom associated with the use of the medicine.


Q: Does Crismol interact with blood pressure medication?

Caution is advised when combining Crismol with medicines that lower blood pressure. This is because the combination may result in additive effects, which could cause symptoms like dizziness or changes in pulse.


Q: What does the term 'off-label' mean in relation to a drug like Crismol?

The term 'off-label use' describes prescribing a medicine for a purpose not specifically reviewed and approved by regulatory agencies. This includes an unapproved indication, an unapproved age group, or using an unapproved dose or route of administration.


Q: Can Crismol be used for anxiety or stress-related conditions?

The active ingredient in Crismol is approved for use in the treatment of panic disorder. Its fundamental purpose is to stabilize neurological activity, which provides a general calming and anxiolytic effect for relevant conditions.


Q: How long does Crismol stay in a person's system after the last dose?

This is defined by the medicine's half-life, which ranges from approximately 19 to 60 hours. The half-life describes how long it takes for the concentration of the medicine in the body to be reduced by half.


Q: Is Crismol safe to use for a long time (long-term safety profile)?

Regulatory documents indicate that long-term use of the active ingredient is not typically specified for prolonged duration due to the risks of developing tolerance, physical dependence, and potential for withdrawal symptoms upon discontinuation.


Q: Does Crismol have a potential for dependency or addiction?

Yes, the active ingredient in Crismol is a Schedule IV controlled substance. Regulatory documents clearly state that it carries a risk of abuse, misuse, addiction, and physical dependence.


Q: Can Crismol cause stomach upset or digestive issues?

Official regulatory information focuses on Central Nervous System effects, but some less common digestive issues have been reported. These can include an increase in salivation, difficulty having a bowel movement, and tenderness in the stomach area.


Q: What is the typical timeframe for a doctor to review the use of Crismol?

For conditions other than epilepsy, official guidance suggests that a healthcare provider may regularly review whether the medicine is still needed. This is part of the established practice for managing medicines with potential for dependence.


Q: Is the generic version of Crismol available yet?

Yes, the U.S. Food and Drug Administration (FDA) has approved multiple generic versions of the active ingredient, clonazepam. These generic alternatives are available from various manufacturers in the market.


Q: Does the brand name Crismol mean it is a newer drug?

No, the active ingredient in Crismol is considered an established medication. The original brand name formulation was initially approved by the FDA prior to 1982.


Q: Can Crismol affect a person's ability to concentrate?

Yes, the sedative properties of this medicine can affect cognitive function. Official warnings note that the medicine can cause difficulty concentrating and problems with memory.


Q: What kind of monitoring (like blood tests) is sometimes needed while on Crismol?

Monitoring that is sometimes required may include blood tests to measure the level of the active ingredient in the system, as well as liver function tests and a complete blood count (CBC). This monitoring is used to help track the medicine's effects in the system.


Q: Does taking Crismol at a different time of day make a difference?

For some approved uses, official guidance states that once an effective maintenance amount is established, the entire daily amount may be administered as a single dose at night (before retiring). The determination of the best time for administration is part of the prescribing process.


Q: Is there a maximum amount of time someone is allowed to be on Crismol?

For certain conditions, use is generally recommended for short periods, often 2 to 4 weeks. Due to the risk of dependency, regulatory guidance does not typically specify long-term use.


Q: Can Crismol be taken with or without food?

The tablets or liquid formulations of the active ingredient can be administered with or without food. This is a common administration requirement listed in the official patient information.


Q: Is it okay to drive or operate machinery while taking Crismol?

Official regulatory labeling strongly advises against driving, operating heavy machinery, or performing other dangerous activities until a person knows how the medicine affects them. The warning is issued due to the potential risk of impaired thinking and motor skills.


Q: Are there any known interactions between Crismol and alcohol?

Yes, official warnings state that the combination with alcohol should be avoided or limited. This is because it can significantly increase central nervous system side effects such as dizziness, drowsiness, and difficulty concentrating.


Q: What are the rules regarding combining Crismol with other mental health medications?

Caution is advised when combining Crismol with other central nervous system depressants, including certain antipsychotics, antidepressants, or hypnotics. This combination can increase the chance of side effects like excessive drowsiness.


Q: Does Crismol interact with common supplements like multivitamins or St. John's Wort?

Official information advises against taking the active ingredient with certain herbal remedies, such as St. John's Wort. These supplements may either increase the drowsy effects or potentially reduce the medicine's overall effectiveness.


Q: Are there reports of Crismol causing vision changes?

Blurred vision is among the potential side effects of medicines in this class. Regulatory agencies caution that such effects may interfere with daily activities like driving or operating machinery.


Q: What does the research say about Crismol use in the pediatric population?

For seizure disorders, dosage guidelines are established for children aged 10 and older. However, use for panic disorder in patients under 18 years of age is not established in regulatory documents.


Q: Why do some people say they feel energized while taking Crismol?

Official safety warnings note the possibility of paradoxical reactions. These are effects opposite to the expected calming, which include unusual excitement, agitation, or irritability. These reactions may occur in some individuals.

How should Crismol be stored and disposed of?

How to Store and Dispose of Crismol

Crismol (Clonazepam) must be stored under specific conditions to maintain its effectiveness. Regulatory labeling mandates storing the tablets at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F), and explicitly warns against freezing the product. The medicine must be kept in its tight, light-resistant container and protected from moisture and direct light.

Child Safety and Disposal

For child safety, Crismol must be stored out of the sight and reach of children, and the container requires a child-resistant closure. Expired or unused Crismol should be disposed of immediately via a drug take-back program or specific household trash method as described by local authorities. The product is not approved to be flushed down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Crismol found in:

A-Z Index: